抗新冠肺炎强身功运动处方对新冠肺炎康复患者肺功能和生活质量的影响:随机对照试验研究方案
本研究为平行设计、两臂、分析者盲的随机对照试验,计划招募60例20至80岁新冠肺炎后遗症出院患者,按1:1随机分配至世界卫生组织指导的呼吸技术组和抗新冠肺炎强身功运动处方组,两组均每日锻炼两次、持续3个月,主要结局为改良医学研究委员会呼吸困难量表,次要结局包括改良Borg量表、疲劳量表-14、患者健康问卷-9、匹兹堡睡眠质量指数和呼吸道症状量表,并在锻炼前、锻炼后3个月和随访3个月时评估。
要点
- 研究纳入60例新冠肺炎后遗症出院患者,随机分为呼吸技术组和抗新冠肺炎强身功组。
- 两组均每日锻炼两次、持续3个月,主要结局为改良医学研究委员会呼吸困难量表。
- 次要结局包括改良Borg量表、疲劳量表-14、患者健康问卷-9、匹兹堡睡眠质量指数和呼吸道症状量表。
核心结论
- 该试验将为抗新冠肺炎强身功运动处方治疗新冠肺炎出院患者康复期的价值提供高质量证据。
研究设计与样本
- 平行设计、两臂、分析者盲的随机对照试验,计划招募60例20至80岁新冠肺炎后遗症出院患者,按1:1随机分配至呼吸技术组和抗新冠肺炎强身功运动处方组。
关键数值与推荐
- 两组均每日锻炼两次、持续3个月。
- 主要结局为改良医学研究委员会呼吸困难量表。
- 次要结局包括改良Borg量表、疲劳量表-14、患者健康问卷-9、匹兹堡睡眠质量指数和呼吸道症状量表。
- 临床量表在锻炼前、锻炼后3个月和随访3个月三个时间点评估。
- 不良事件将记录用于安全性评估。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Since early 2022, patients with 2019 novel coronavirus (COVID-19) infection have increased rapidly in Shanghai, China. Nevertheless, there is no widely used unified rehabilitation treatment available for discharged patients with post-infection sequelae such as dyspnea, depression, and fatigue. To promote the rehabilitation of discharged patients, our team formulated Kangyi Qiangshen Gong exercise prescription on the basis of traditional Chinese medicine rehabilitation exercises (TCMRE). We designed a randomized controlled trial to evaluate the efficacy of rehabilitation and advantages of KQG for discharged patients with post-COVID-19 syndrome. METHODS/DESIGN: This is a parallel-design, two-arm, analyst assessor-blinded, randomized controlled trial. In total, 60 discharged patients with COVID-19 sequelae, aged from 20 to 80 years will be recruited and randomly assigned to the World Health Organization instructed breathing techniques (BT) group and the Kangyi Qiangshen Gong exercise prescription (KQG) group at a ratio of 1:1. The patients in the BT group will perform breathing techniques exercise, and the patients in the KQG group will perform KQG exercise. Both groups will perform exercises twice a day for 3 months. The primary outcome will be measured with the Modified Medical Research Council Dyspnea Scale, and the secondary outcomes will include the Modified Borg Scale, Fatigue Scale-14, Patient Health Questionnaire-9 Scale, Pittsburgh Sleep Quality Index, and the Respiratory Symptoms Scale. Clinical scales will be assessed at three points (pre-exercise, 3 months post-exercise, and 3 months follow-up). Adverse events will be recorded for safety assessment. DISCUSSION: This trial will serve high-quality evidence of the value of KQG for treating discharged patients with COVID-19 in rehabilitation period. TRIAL REGISTRATION: Chinese Clinical Trial Registry ChiCTR2200059504. Registered on 03 May 2022. DISSEMINATION: The results will be published in peer-reviewed journals and disseminated through the study's website, and conferences.
引用
- Guo G, Xu X, Yin WY, et al. Kangyi Qiangshen Gong exercise prescription for pulmonary function and quality of life in patients recovered from COVID-19: a study protocol for a randomized controlled trial. Trials. 2022. PMID: 36242061. doi:10.1186/s13063-022-06817-5
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。